Toso
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsGARRY P. NOLAN, YASUMICHI HITOSHI
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel polypeptides such as the the Toso protein and related molecuels which have an inhibitory effect on TNF mediated apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologouspolypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims34
A recombinant nucleic acid encoding a Toso protein that will hybridize under high stringency conditions to the nucleic acid sequence depicted in FIG. 1 (SEQ ID NO:1) or its complement.
A recombinant nucleic acid encoding a Toso protein that is at least about 70% identical to the amino acid sequence depicted in FIG. 1 (SEQ ID NO:
- 1).
A Toso protein encoded by a nucleic acid that will hybridize under high stringency conditions to the complement of the nucleic acid sequence depicted in FIG. 1 (SEQ ID NO:
- 1).
A recombinant Toso protein that is at least about 70% identical to the amino acid sequence depicted in FIG. 2a (SEQ ID NO:2).
A method of modulating apoptosis in a cell comprising administering to said cell a recombinant nucleic acid encoding a Toso protein.
A mammalian cell comprising a modified Toso cell surface receptor.
A method for treating an apoptosis related condition in a mammal comprising administering a recombinant nucleic acid encoding a Toso protein.
A method for treating an apoptosis related condition in a mammal comprising administering a Toso protein.
A method for treating an apoptosis related condition in a mammal comprising administering an anti-Toso antibody.
Dependencies are inferred from the claim text.